Management of Severe and Moderate Hypercholesterolemia in Young Women and Men

JAMA Cardiol. 2022 Feb 1;7(2):227-230. doi: 10.1001/jamacardio.2021.4983.

Abstract

This study uses clinical registry data to assess achievement of low-density lipoprotein cholesterol reduction and lipid-lowering therapy prescribing patterns among adults aged 20 to 39 years with moderate to severe hypercholesterolemia.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anticholesteremic Agents / therapeutic use*
  • Cholesterol, LDL / blood
  • Disease Management
  • Ezetimibe / therapeutic use*
  • Female
  • Guideline Adherence
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Male
  • PCSK9 Inhibitors / therapeutic use*
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Registries
  • Severity of Illness Index
  • Sex Factors
  • Young Adult

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 Inhibitors
  • Ezetimibe